659729-78-9

Usage

Uses

Used in Pharmaceutical Research:
2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI) is used as a research compound for its potential biological activities and pharmacological properties. Its unique structure, including the quinoxaline ring, amino, and methoxy groups, may contribute to its efficacy in various therapeutic areas, making it a valuable candidate for drug development.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI) is utilized as a starting material or a building block for the synthesis of new pharmaceutical agents. Its chemical properties and structural features can be leveraged to create novel compounds with improved therapeutic profiles, including enhanced potency, selectivity, and reduced side effects.
Used in Drug Discovery:
2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI) serves as a key component in drug discovery processes, where it may be evaluated for its interaction with various biological targets. Its potential to modulate these targets could lead to the identification of new therapeutic agents for the treatment of a range of diseases and conditions.
Used in Biochemical Studies:
In biochemical research, 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI) is employed to investigate its interactions with enzymes, receptors, and other biomolecules. Understanding these interactions can provide insights into the compound's mechanism of action and its potential applications in medicine.
While the specific applications and uses of 2(1H)-Quinoxalinone,3-amino-8-methoxy-(9CI) may vary depending on the outcomes of ongoing research, its presence in the pharmaceutical and medicinal chemistry domains highlights its potential as a versatile and promising compound for future therapeutic development.

InChI:InChI=1/C9H9N3O2/c1-14-6-4-2-3-5-7(6)12-9(13)8(10)11-5/h2-4H,1H3,(H2,10,11)(H,12,13)

Upstream product

• 816-27-3 ethyl 2-ethoxy-2-iminoacetate 
• 83009-35-2 ethoxy-imino-acetic acid ethyl ester 

Downstream Products

• 659729-80-3 3-amino-8-hydroxy-1H-quinoxalin-2-one 

Relevant academic research and scientific papers

Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate

A series of novel 4-oxopyrimidine TRPV1 antagonists was evaluated in assays measuring the blockade of capsaicin or acid-induced influx of calcium into CHO cells expressing TRPV1. The investigation of the structure-activity relationships in the heterocyclic A-region revealed the optimum pharmacophoric elements required for activity in this series and resulted in the identification of subnanomolar TRPV1 antagonists. The most potent of these antagonists were thoroughly profiled in pharmacokinetic assays. Optimization of the heterocyclic A-region led to the design and synthesis of 23, a compound that potently blocked multiple modes of TRPV1 activation. Compound 23 was shown to be effective in a rodent "on-target" biochemical challenge model (capsaicin-induced flinch, ED50 = 0.33 mg/kg p.o.) and was antihyperalgesic in a model of inflammatory pain (CFA-induced thermal hyperalgesia, MED = 0.83 mg/kg, p.o.). Based on its in vivo efficacy and pharmacokinetic profile, compound 23 (N-{4-[6-(4-trifluoromethyl-phenyl)-pyrimidin-4-yloxy]-benzothiazol-2-yl} -acetamide; AMG 517) was selected for further evaluation in human clinical trials.

VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS

Pyrimidine ethers and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

Vanilloid receptor ligands and their use in treatments

Compounds having the general structure and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache,